Start the conversation
If you've been with us for any length of time, you've heard me say this before: On a beaten-down stock, the single-best "Buy" signal is insider buying.
It's also a pretty good signal with stocks up near record highs - as the Nasdaq Composite Index continues to be after a third-quarter surge of 9.7% (its best since 2013).
And one small biotech I've been watching fits the bill.
We've seen insider buying. We're also seeing strong buying by the "knowledgeable outsiders" we also refer to as "Frontrunners" because of their propensity for identifying stocks with hefty upside possibilities.
The company in question: Minerva Neurosciences Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical firm that's pushing ahead with a whole portfolio of drug candidates targeting central nervous system (CNS) diseases.
And there's been a lot of buying by both corporate insiders and outside "frontrunner" investors with a long track record for identifying biotech winners.
Let's take a look...
This is premium content for Private Briefing subscribers only.